EUVIMEDEUVIMED entdecken
Open Access

Stress‑induced catecholamines attenuate sorafenib efficacy by inhibiting ferroptosis in β2‑adrenergic receptor positive renal cell carcinoma

Masaki Ushijima, Sei Naito, Hiromi Ito, Takafumi Narisawa, Osamu Ichiyanagi, Hidenori Kanno, Hiroki Fukuhara, Yuki Takai, Mayu Yagi, Atushi Yamagishi, Hayato Nishida, Yutaro Obara und 1 weitere

International Journal of Oncology · 22.06.2026 · 69 (2) · 1-14

DOI: 10.3892/ijo.2026.5905 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Oncology, online erschienen am 22.06.2026. Verfasst von Masaki Ushijima und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Yamagata University Faculty of Medicine, Yamagata 990‑9585, Japan. Hauptthemen laut MEDLINE: Sorafenib, Ferroptosis, Receptors, Adrenergic, beta-2, Carcinoma, Renal Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ferroptosis, an iron‑dependent form of non‑apoptotic cell death, is a potential target for cancer therapy. Sorafenib, a molecular targeted agent for renal cell carcinoma (RCC), is involved in ferroptosis induction. Chronic stress, mediated by catecholamines via β2‑adrenergic receptors (ADRB2), promotes cancer progression, yet its influence on drug resistance and ferroptosis remains elusive. To investigate ADRB expression in RCC, immunohistochemistry of surgical specimens was performed and assessed ADRB mRNA and protein levels were assessed by RT‑qPCR and western blotting in RCC cell lines. To determine whether β‑adrenergic signaling modulates sorafenib sensitivity, we used ADRB2‑expresing ACHN cells and conducted MTS cell viability assays following β‑adrenergic agonist isoproterenol (ISO) stimulation, ADRB2 knockdown by siRNA, as well as a restraint‑stress mouse model in which catecholamine levels were elevated, bearing ACHN cells or ACHN cells with ADRB2 knockdown by shRNA. To evaluate the involvement of ferroptosis, we applied the ferroptosis inhibitor ferrostatin‑1 (Fer‑1) and inducers erastin and RSL3, and measured cell viability, malondialdehyde and reactive oxygen species. To elucidate the mechanism underlying the ISO effect on ferroptosis, MAPK pathway activity was assessed by western blotting and MTS assays performed under MAPK inhibition. The present study confirmed ADRB2 expression in RCC by immunohistochemistry of surgical specimens. Using the ADRB2‑expressing RCC cell line ACHN, the present study demonstrated that stimulation with the β‑adrenergic agonist isoproterenol (ISO) conferred resistance to sorafenib both in vitro and in a mouse stress model; this effect was abrogated by ADRB2 knockdown. Similarly to ISO, Fer‑1 diminished sorafenib sensitivity in ACHN cells. Erastin and RSL3 markedly decreased cell viability, however, ISO attenuated ferroptosis in ACHN cells. Mechanistically, ISO inhibited the phosphorylation of ERK1/2, p38 and JNK, all of which contribute to ferroptosis suppression. These findings provide evidence that chronic stress‑induced ADRB2 activation promotes sorafenib resistance by mitigating ferroptotic cell death.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibFerroptosisReceptors, Adrenergic, beta-2Carcinoma, Renal CellKidney NeoplasmsCatecholaminesAnimalsHumansMiceCell Line, TumorMaleDrug Resistance, NeoplasmFemaleIsoproterenolMiddle AgedCell Survival

Stichwörter der Autor:innen

ferroptosisrenal cell carcinomasorafenibstressβ2‑adrenergic receptor

Substanzen

SorafenibReceptors, Adrenergic, beta-2ADRB2 protein, humanCatecholaminesIsoproterenol

Autor:innen und Institutionen

  • Department of Urology, Yamagata University Faculty of Medicine, Yamagata 990‑9585, Japan.
  • Department of Pharmacology, Yamagata University Faculty of Medicine, Yamagata 990‑9585, Japan.

Zitieren

APA

Ushijima, M., Naito, S., Ito, H., Narisawa, T., Ichiyanagi, O., Kanno, H., Fukuhara, H., Takai, Y., Yagi, M., Yamagishi, A., Nishida, H., Obara, Y., & Tsuchiya, N. (2026). Stress‑induced catecholamines attenuate sorafenib efficacy by inhibiting ferroptosis in β2‑adrenergic receptor positive renal cell carcinoma. International Journal of Oncology, 69(2), 1-14. https://doi.org/10.3892/ijo.2026.5905

Vancouver

Ushijima M, Naito S, Ito H, Narisawa T, Ichiyanagi O, Kanno H, et al. Stress‑induced catecholamines attenuate sorafenib efficacy by inhibiting ferroptosis in β2‑adrenergic receptor positive renal cell carcinoma. International Journal of Oncology. 2026;69(2):1-14. doi:10.3892/ijo.2026.5905

BibTeX
@article{Ushijima2026,
  author = {Ushijima, Masaki and Naito, Sei and Ito, Hiromi and Narisawa, Takafumi and Ichiyanagi, Osamu and Kanno, Hidenori and Fukuhara, Hiroki and Takai, Yuki and Yagi, Mayu and Yamagishi, Atushi and Nishida, Hayato and Obara, Yutaro and Tsuchiya, Norihiko},
  title = {Stress‑induced catecholamines attenuate sorafenib efficacy by inhibiting ferroptosis in β2‑adrenergic receptor positive renal cell carcinoma},
  journal = {International Journal of Oncology},
  year = {2026},
  volume = {69},
  number = {2},
  pages = {1--14},
  doi = {10.3892/ijo.2026.5905}
}
Kostenlos starten →